Review Article

Drug-Drug Interactions in Melanoma

LeAnn B. Norris, PharmD, FCCP, BCPS, BCOP

University of South Carolina College of Pharmacy, Columbia, South Carolina

Author’s disclosures of conflicts of interest are found at the end of this article.

LeAnn B. Norris, PharmD, BCPS, BCOP, FCCP, University of South Carolina College of Pharmacy, 715 Sumter Street, Columbia, SC 29208. E-mail: norris@cop.sc.edu


J Adv Pract Oncol 2018;9(suppl 1):73–78 | https://doi.org/10.6004/jadpro.2018.9.7.16 | © 2018 Harborside™


  

ABSTRACT

Abstract

Tyrosine kinase inhibitors are indicated for the treatment of a variety of malignancies, but are used commonly in patients with advanced melanoma. Most are also substrates for various efflux transporters, including P-glycoprotein. Due to the frequent use of these agents and the metabolism pathway, serious drug-drug interactions are an increasing risk. This review will focus on both the pharmacokinetic and pharmacodynamic interactions with these agents. Most interactions concern altered bioavailability due to altered stomach pH, metabolism by cytochrome P450 isoenzymes, and prolongation of the QTc interval. This review provides recommendations to guide all advanced practitioners for managing drug-drug interactions, dosing modifications, and drugs to avoid. A complete medication review along with open communication is extremely important within the multidisciplinary health-care team.




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2018 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.